Avexis buy endorses gene therapy and gives Biogen a headache
After Solid Biosciences’ clinical hold dealt gene therapy a body blow Novartis has ridden to the technology’s rescue. The Swiss firm’s $8.7bn takeover of Solid’s peer Avexis will be seen as a strong endorsement of gene therapy, especially given the premium – nearly double Avexis’s closing price on Friday.
Indeed, Solid’s problems, with a Duchenne muscular dystrophy project, had been seen as having a direct readthrough to Avexis’s work in spinal muscular atrophy – both gene therapies use the AAV9 vector. Investors will no doubt take comfort in the boldness of the takeover, the first big move by Novartis’s recently appointed chief executive, Vas Narasimhan.
Overall, the acquisition is in line with Mr Narasimhan’s aim of taking Novartis into approaches using ever more advanced technologies. Bernstein analysts today pointed out that a recent meeting with the group’s chief financial officer, Harry Kirsch, highlighted gene therapy as an area of interest.
It will also not go unnoticed that Avexis is studying its lead, AVXS-101, in spinal muscular atrophy (SMA), which has in recent years seen significant industry involvement. No doubt interest has been piqued by Biogen/Ionis’s Spinraza, an antisense therapy that in 2016 became the first disease-modifying SMA treatment, and is expected to generate 2022 sales of $2.2bn, according to EvaluatePharma consensus.
And Novartis itself has shown interest in SMA: it has two mid-stage assets, BVS857 and LMI070/branaplam, though at present only the latter seems to be in active development. Today Jefferies speculated that Biogen might have been interested in Avexis to bolster its SMA offering, though the analysts thought Roche was more likely to have come up with a takeover.
Avexis is curious in that it had received interest from Roche before the Swiss group’s local rival, Novartis, tabled today’s knockout bid.
Roche had employed a multi-pronged SMA approach: in 2011 it struck a deal with PTC Therapeutics covering gene splicing modifiers, before buying the private group Trophos for its lead asset, olesoxime, in 2015; Roche also participated in Avexis’s series D financing, and had an option over AVXS-101, then known as chariSMA.
Though olesoxime had shown significant promise initially, it is at present only in one actively enrolling trial, Oleos; RG7916, one of its two PTC-derived assets, is presently Roche’s main focus in SMA.
|Key projects for spinal muscular atrophy (SMA)|
|Product||Company||Mechanism of action||2022e sales ($m)||Status|
|AVXS-101||Avexis (Novartis)||SMN1 gene therapy||1,376||Phase III|
|RG6083/olesoxime||Roche (formerly Trophos)||Mitochondrial pore modulator||9||Phase II|
|RG7916||Roche/PTC||SMN2 splicing modifier||6||Phase II|
|LMI070||Novartis||SMN2 splicing modifier||5||Phase II|
|CK-2127107||Astellas/Cytokinetics||Troponin activator||-||Phase II|
For Novartis, of course, AVXS-101 is Avexis’s key attraction. The project is intended as a one-time treatment to restore production of the SMN protein, whose deficiency, primarily owing to mutations in the SMN1 gene, is the main cause of SMA. Pivotal trials are still ongoing, but in the meantime a pre-BLA meeting is due to take place with the US regulator.
Novartis today said it was targeting a 2019 filing in the US, a delay versus Avexis’s second-half 2018 expectation. AVXS-101’s clinical programme comprises various studies in different types of SMA, while the key supporting data generated so far concern the 15 type 1 patients enrolled into the CL-101 trial, 100% of whom were alive and event-free at 20 months’ follow-up.
While the only available comparison versus Spinraza is across studies, this favours Avexis; the Endear trial showed Spinraza beating placebo in a broadly similar subject population to that studied in CL-101, but one-year event-free survival, a secondary endpoint, was around 60% in the active group.
Across-study or not, many analysts now see AVXS-101 as a major threat to Spinraza. Bernstein today wrote that Novartis’s takeover ratcheted up the pressure on Biogen, putting the main competing SMA programme in the hands of a “well-funded, payer-competent, global-reaching company”.
The analysts said they had for some time been concerned that sellside consensus was underestimating the Avexis threat. Given where Spinraza’s 2022 revenue consensus stands the scope for this to be trimmed is considerable.
|Selected studies of AVXS-101|
|Study||SMA type||Disease characteristics||Design||Trial ID|
|CL-101||Type 1||2 SMA2 gene copies; 90% death by age 2||15 pts, open-label (100% 20mth event-free survival)||NCT02122952|
|Str1ve||Type 1||2 SMA2 gene copies; 90% death by age 2||15 pts, single-arm||NCT03306277|
|Strong||Type 2||3 SMA2 gene copies; 32% death by age 25||27 pts, open label||NCT03381729|
|Spr1nt||Presymptomatic||–||44 pts, single-arm||Planned Q2 2018|
|Reach||Types 1, 2 & 3||Type 3 have 3 or 4 SMA2 copies; normal survival||50 pts, single-arm||Planned Q1 2019|
To contact the writer of this story email Jacob Plieth in London at [email protected] or follow @JacobPlieth on Twitter